Iradimed Corporation (NASDAQ:IRMD) Short Interest Update

Iradimed Corporation (NASDAQ:IRMD) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 105,000 shares, a growth of 22.0% from the November 30th total of 86,100 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily volume of 39,100 shares, the days-to-cover ratio is currently 2.7 days.

Insiders Place Their Bets

In other news, CFO John Glenn sold 2,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total transaction of $135,450.00. Following the sale, the chief financial officer now owns 4,383 shares in the company, valued at approximately $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 37.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Iradimed

Several institutional investors have recently modified their holdings of IRMD. Charles Schwab Investment Management Inc. raised its position in shares of Iradimed by 189.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider’s stock valued at $3,351,000 after buying an additional 43,635 shares during the last quarter. Eagle Asset Management Inc. purchased a new position in Iradimed in the 3rd quarter worth approximately $1,239,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Iradimed by 14.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 20,122 shares of the medical equipment provider’s stock worth $1,012,000 after purchasing an additional 2,538 shares during the last quarter. Albert D Mason Inc. purchased a new stake in shares of Iradimed in the third quarter valued at approximately $737,000. Finally, Barclays PLC increased its holdings in shares of Iradimed by 113.9% in the third quarter. Barclays PLC now owns 23,774 shares of the medical equipment provider’s stock valued at $1,196,000 after purchasing an additional 12,657 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

Iradimed Price Performance

IRMD stock traded down $0.09 during trading on Tuesday, hitting $55.00. 21,902 shares of the company traded hands, compared to its average volume of 48,271. Iradimed has a 1 year low of $40.18 and a 1 year high of $57.95. The stock’s 50-day simple moving average is $53.46 and its 200 day simple moving average is $48.94. The company has a market cap of $697.02 million, a PE ratio of 37.67 and a beta of 0.82.

Iradimed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were given a dividend of $0.15 per share. The ex-dividend date was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.09%. Iradimed’s dividend payout ratio (DPR) is 41.10%.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.